BUSINESS

• Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
  November 28, 2016

• Shionogi Set to Go Global with Botulinum Toxin, Gets Rights from Tokushima Univ.
  November 25, 2016

• CSL Behring to Enter Japanese Hemophilia Market with Idelvion
  November 25, 2016

• MSD to Distribute Bayer’s Adempas from Next Year
  November 25, 2016

• Ninlaro Earns Conditional Approval in Europe: Takeda
  November 25, 2016

• Gynecologist Calls for Correct Understanding of Hormonal Products
  November 24, 2016

• 27 Japan Drug Makers Eke Out Profit despite Logging Lower Sales on FX, Price Cuts: Jiho Tally
  November 24, 2016

• Empliciti “Extremely Promising” in the Treatment of Multiple Myeloma: Hematologist
  November 24, 2016

• Fujifilm Hooks Up with China Resources in Healthcare
  November 22, 2016

• Taltz Finally Makes it to Japan Market after Pricing Flap
  November 22, 2016

• Empliciti, Batch of Other Drugs Go on Sale in Japan
  November 21, 2016

• 3 Japan Generic Majors See Subdued Sales Rise in April-September
  November 21, 2016

• Invalidation Ruling for Evista Upheld: Sawai
  November 21, 2016

• Eisai’s BACE Inhibitor Gets FDA’s Fast-Track Status
  November 21, 2016

• AbbVie to File for Dual Hep C Treatments Offering Shorter Treatment Time than Harvoni, Sovaldi
  November 18, 2016

• Sanofi Begins Praluent Post-Marketing Study in Japanese ACS Patients
  November 17, 2016

• Sanofi Japan Looks to Launch 20-Plus Products by 2020: New Chief
  November 17, 2016

• Ono Braces for “Unexpected Negative Impact” from Price Cut, Calls for Stable Rules
  November 17, 2016

• Japan CNS Market to Reach 648.7 Billion Yen in 2024: Fuji Keizai
  November 17, 2016

• First DOAC Antidote to Hit Japan Market This Month
  November 16, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 460
• 461
• 462
• 463
• 464
• 465
• 466
• 467
• 468
• …
• Next ›
• 最終 »